molecules of the month


highly selective NaV1.6 sodium channel inh.

entering Ph. II for seizures (100 mg TID)

arylsulfonamide class


Xenon Pharmaceuticals, Burnaby, Canada

1 min read

The Xenon NaV1.6 Inhibitor, NBI-921352, is remarkably selective for the NaV1.6 sodium channel over other isoforms (IC50 = 51 nM, 756x vs. NaV1.1, 134X vs. NaV1.2, 276X vs. NaV1.7, >583X vs. 1.3, 1.4, 1.5). The molecule is It is being developed to treat pediatric patients with SCN8A developmental and epileptic encephalopathy (SCN8A-DEE) and other indications such as adult focal epilepsy. The molecule is an arylsulfonamide and has a similar structure to NaV1.7 arylsulfonamide inhibitors, and is a state-dependent inhibitor, preferentially inhibiting activated channels. The molecule was well-tolerated in a Ph. I study at plasma concentrations greater than required for efficacy in preclinical studies, and efficacy will soon be evaluated in Ph. II. NBI-921352 appears to be effective in preventing seizures at…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: